News & Events
-
August 30, 2023
Fall 2023 HRA Members Meeting
This October 16-17, in Chicago, IL members of C-Path’s CDRC team will join the Health Research Alliance’s Members Meeting. The Health Research Alliance is a collaborative member organization of nonprofit research funders committed to maximizing the impact of biomedical research to improve human health. CDRC Senior Scientific Director Smith Heavner, will present on repurposing treatments...... -
August 29, 2023
Externally-Led Patient Focused Drug Development
C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) and the PKD Foundation will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for Autosomal Recessive Polycystic Kidney Disease (ARPKD) on Tuesday, August 29th. EL-PFDD meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, physicians, and researchers who are...... -
August 25, 2023
C-Path’s Romero Appears on The BioCentury Show
Klaus Romero, Chief Science Officer at Critical Path Institute, occupies a rare role in the industry, as the top scientist in an organization whose mission is to solve industry-wide bottlenecks in drug development, with a path that leads directly to endorsement by FDA and other regulatory bodies. On the latest episode of The BioCentury Show, Romero...... -
August 25, 2023
C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium
AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson’s disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine...... -
August 25, 2023
C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials
This memo outlines how C-Path can contribute as a key strategic regulatory partner to the Innovative Health Initiative’s (IHI) call 4, “Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases.” We encourage potential partners to review the memo and reach out as early as possible to rdcadap@c-path.org with interest. On 27 July 2023, the......